In this study, participants with locally advanced rectal cancer patients will be treated
according to MMR/MSI status. There will be two cohorts in this study: Cohort A and Cohort B.
For Cohort A, dMMR or MSI-H patients will receive neoadjuvant Pd1 antibody Sintilimab and
surgery or watch and wait, followed by adjuvant treatment. For Cohort B, pMMR/MSS/MSI-L
patients will be randomized to receive neoadjuvant chemoradiotherapy Pd1 antibody
Sintilimab followed by surgery or watch and wait, and adjuvant treatment.
Colorectal Cancer Stage II, Colorectal Cancer Stage III, Mmr Deficiency, MSI-H
Total Mesorectal Excision,
Watch and wait
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.